Premium
Biomarker discovery in autoimmune diseases via immobilized capture agents
Author(s) -
Tan Niclas,
Gurnani Prem,
Nandi Animesh,
Rosenblatt Kevin,
Kodadek Thomas
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.lb67
Subject(s) - proteomics , biomarker discovery , biomarker , computational biology , multiple sclerosis , dna microarray , medicine , disease , immunology , biology , pathology , gene expression , gene , genetics
Biomarker discovery through differential patterns of expression has become a common practice in genomics and proteomics studies. A favorite in large‐scale gene expression analysis, the use of DNA microarrays has been hampered by technical difficulties in their production. In contrast, the widely used surface enhanced laser desorption/ionization mass spectrometry (SELDI MS) technology has shown great potential in differential protein profiling of diseases. In the present study, we performed a comparative analysis of the protein expression profiles in cerebrospinal fluid (CSF) and serum from clinical samples from patients diagnosed with either multiple sclerosis (MS) or narcolepsy versus controls. A set of discriminatory biomarker candidates was obtained for each respective autoimmune disease. Currently, these two autoimmune diseases lack reliable biomarkers for early diagnosis purposes. Therefore, the further characterization and identification of these potential biomarkers will provide invaluable insight into the pathogenesis of these diseases. This work was supported by National Heart, Lung, and Blood Institute (NHLBI) for University of Texas Southwestern Proteomics Research.